<div id="readability-page-1">US stock futures are slightly lower this Wednesday morning, but several individual stocks are making sharp moves on index changes, FDA approvals, earnings, and corporate actions. Here are the stocks investors are watching today: UiPath (PATH) Surged after S&amp;P Dow Jones Indices announced UiPath will join the S&amp;P MidCap 400, replacing Synovus Financial, effective January 2, 2026. Shares jumped 6.8 percent to $17.05 in after-hours trading. Agios Pharmaceuticals (AGIO) Announced FDA approval of Mitapivat (EcVSmi) to treat anemia in adults with alpha or beta thalassemia. Despite the approval, shares slipped 1.4 percent to $24.59. Fight BioPharma (FIGHT) Announced a 1-for-3000 reverse stock split, sending shares down 28.8 percent to $0.17 after hours. Cush Pharmaceuticals (CUSH) Delivered better-than-expected Q4 results, posting a $0.11 loss per share versus estimates of a $0.43 loss. Shares surged 22.1 percent to $1.27 after hours. Ramaco Resources (METC) Jumped 7.1 percent to $18.09 after announcing a $100 million share buyback program.</div>

Agios制药

METC

PATH

<p>美国股指期货略微下跌，但个股却出现剧烈波动。UiPath 在加入标准普尔中型股 400 指数后上涨 6.8%。尽管 Agios Pharmaceuticals 获得了 FDA 对 Mitapivat 的批准，但股价仍下跌 1.4%。Fight BioPharma 在进行反向股票拆分后下跌 28.8%。Cush Pharmaceuticals 因第四季度业绩好于预期上涨 22.1%。Ramaco Resources 在宣布 1 亿美元的股票回购计划后上涨 7.1%</p>

今天需要关注的五只股票 | 股市在圣诞前夕开放